

Publikationen – Prof. Dr. med. Inka Wiegratz (Auswahl):

Wiegratz I, Jung-Hoffmann C, Kuhl H.

Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins.

Contraception 1995;51:341-6

Kuhl H, Jung-Hoffmann C, Wiegratz I.

Gestodene-Containing Contraceptives.

Clin Obstet Gynecol 1995;38:829-40

Wiegratz I, Hertwig B, Jung-Hoffmann C, Kuhl H.

Inhibition of low-density lipoprotein oxidation in vitro and ex vivo by several estrogens and oral contraceptives.

Gynecol Endocrinol 1996;10:149-52

Wiegratz I, Jung-Hoffmann C, Kuhl H.

Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon different lipid and lipoprotein parameters.

Contraception 1998;58:83-91

Wiegratz I, Fink T, Rohr UD, Lang E, Leukel P, Kuhl H.

Überkreuz-Vergleich der Pharmakokinetik von Estradiol unter der Hormonsubstitution mit Estradiolvalerat oder mikronisiertem Estradiol.

Zentralbl Gynäkol 2001;123:505-12

Wiegratz I, Starflinger F, Tetzloff W, Leifels-Fischer B, Helmond FA, Dericks-Tan JSE, Kuhl H.

Effect of tibolone compared with sequential hormone replacement therapy on carbohydrate metabolism in post-menopausal women.

Maturitas 2002;26;41:133-41

Wiegratz I, Kuhl H.

Managing cutaneous manifestations of hyperandrogenic disorders.

Treat Endocrinol 2002;1:373-86

Wiegratz I, Lee JH, Kutschera E, Bauer HH, von Hayn C, Moore C, Mellinger U, Winkler UH, Groß W, Kuhl H.

Effect of Dienogest containing oral contraceptives on lipid metabolism.

Contraception 2002;65:223-9

Wiegratz I, Sängler N, Kuhl H.

Formation of 7 α -methyl-ethinylestradiol during treatment with tibolone.

Menopause 2002;9(4):293-5

Wiegratz I, Kutschera E, Lee JH, Moore C, Mellinger U, Winkler UH, Kuhl H.

Effect of four different oral contraceptives on various sex hormones and serum-binding globulins.

Contraception 2003;67:25-32

Wiegratz I, Kutschera E, Lee JH, Moore C, Mellinger U, Winkler UH, Kuhl H.

Effect of four oral contraceptives on thyroid hormones, adrenal and blood pressure parameters.

Contraception 2003;67:361-6

Wiegratz I, Hommel HH, Zimmermann T, Kuhl H.
Attitude of German women and gynecologists towards long-cycle treatment with oral contraceptives.
Contraception 2004;69:37-42

Wiegratz I, Kuhl H.
Progestogen therapies: differences in clinical effects?
Trends Endocrin Metab 2004;15:277-85

Wiegratz I, Lee JH, Kutschera E, Winkler UH, Kuhl H.
Effect of four oral contraceptives on haemostasis parameters
Contraception 2004;70:97-106

Wiegratz I, Kuhl H.
Long-cycle treatment with oral contraceptives.
Drugs 2004;64:2447-62

Wiegratz I, Mittmann K, Dietrich H, Zimmermann T, Kuhl H.
Fertility after discontinuation of treatment with an oral contraceptive containing 30 µg of ethinyl estradiol and 2 mg of dienogest.
Fertil Steril 2006;85:1812-9

Kissler S, Hamscho N, Zangos S, Wiegratz I, Schlichter S, Menzel C, Doebert N, Gruenwald F, Vogl TJ, Gaetje R, Siebzehrnuebl E, Kunz G, Leyendecker G, Kaufmann M.
Uterotubal transport disorder in adenomyosis and endometriosis – a cause for infertility.
BJOG 2006;113:902-8

Wiegratz I, Kuhl H.
Metabolic and clinical effects of progestogens.
Eur J Contracept Repr 2006;11:153-61

Wiegratz I, Kissler S, Kuhl H, Kaufmann M.
Extended and continuous use of hormonal contraceptives to reduce menstruation.
Womens's Health 2006;2:705-16

Kissler S, Zangos S, Wiegratz I, Kohl J, Rody A, Gaetje R, Doebert N, Wildt L, Kunz G, Leyendecker G, Kaufmann M.
Utero-tubal sperm transport and its impairment in endometriosis and adenomyosis.
Ann N Y Acad Sci 2007;1101:38-48

Wiegratz I, Kuhl H.
High estrogenic impact on the liver by transdermal contraceptive patch
Expert Rev Obstet Gynecol 2007;2:15-8

Kuhl H, Wiegratz I.
Can 19-nortestosterone derivatives be aromatized in the liver of adult humans?
Are there clinical implications?
Climacteric 2007;10:344-353

Sänger N, Stahlberg S, Manthey T, Mittmann K, Mellinger U, Lange E, Kuhl H, Wiegratz I.
Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on thyroid hormones and androgen parameters: conventional vs. extended-cycle use.
Contraception 2008;77:420-5

Wiegratz I, Stahlberg S, Manthey T, Sanger N, Mittmann K, Lange E, Mellinger U, Kuhl H.
Effects of conventional or extended-cycle regimen of an oral contraceptive
containing 30 mcg ethinylestradiol and 2 mg dienogest on various hemostasis
parameters.
Contraception 2008;78:384-391

Kissler S, Zangos S, Kohl J, Wiegratz I, Rody A, Gaetje R, Vogl TJ, Kunz G, Leyendecker G,
Kaufmann M.
Duration of dysmenorrhea and extent of adenomyosis visualised by magnetic resonance
imaging.
Eur J Obstet Gynecol Reprod Biol 2008;137:204-9

Kissler S, Verhoeven, HC, Marx K, Behler M, Emde T, Unterhorst E, Kohl J, Wiegratz I,
Meier W, Scholtes MCW.
Die transvaginale Hydrolaparoskopie (TVHL) – deutsche Erfahrungen uber ein neues
Verfahren in der ambulanten Sterilitatsdiagnostik
Geburtsh Frauenheilk 2009;69:40-4

Wiegratz I, Stahlberg S, Manthey T, Sanger N, Mittmann K, Palombo-Kinne E, Mellinger U,
Lange E, Kuhl H.
Effects of an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on
lipid metabolism during 1 year of conventional or extended-cycle use.
Contraception 2010;81:57-61

Isachenko V, Isachenko E, Nawroth F, Wiegratz I, Kaufmann M, Lapidus I, Hancke K,
Kreienberg R.
Genexpression und morphologie der Follikel nach konventionellem Einfrieren und
Vitrifikation von humanem Ovarialgewebe.
Geburtsh Frauenheilk 2010;70:561-7

Wiegratz I, Stahlberg S, Manthey T, Sanger N, Mittmann K, Palombo-Kinne E, Mellinger U,
Lange E, Kuhl H.
Effects of combined oral contraceptive ethinylestradiol (30µg) and dienogest (2mg) on
carbohydrate metabolism during 1 year of conventional or extended-cycle use.
Horm Metab Res 2010;42:358-363

Wiegratz I, Galilaer K, Sanger N, Rody A, Kuhl H, Schleiner E.
Prescribing preferences and personal experience of female gynaecologists in Germany
and Austria regarding use of extended-cycle oral contraceptives.
Eur J Contracept Reprod Health Care 2010;15:405-12. Epub 2010 Sep 24.

Sanger N, Effenberger KE, Riethdorf S, van Haasteren V, Gauwerky J, Wiegratz I,
Strebhardt K, Kaufmann M, Pantel K.
Disseminated tumor cells in the bone marrow of patients with ductal carcinoma in situ.
Int J Cancer 2011;129:2522-6

Wiegratz I, Thaler CJ.
Hormonal Contraception: what kind, when, and for whom?
Dtsch Arztebl Int 2011;108(28-29):495-506. DOI: 10.3238/arztebl.2011.0495
Hormonale Kontrazeption – was, wann fur wen?
Zertifizierte Fortbildung (CME)
Deutsches Arzteblatt 2011, Jg. 108, Heft 28-29

Birkhäuser M, Kuhl H, Mueck AO, Neulen J, Thaler CJ, Wiegratz I, Wildt L.
45. Arbeitstreffen des „Zürcher Gesprächskreises“ Dezember 2010 mit Kommentar zur
neuen Analyse der Ergebnisse der MARIE-Studie.
Empfehlungen zur Hormontherapie mit Östrogenen und Gestagenen im Klimakterium
und in der Postmenopause
Frauenarzt 2011;52:674-80

Wiegratz I, Stahlberg S, Manthey T, Sängler N, Mittmann K, Lange E, Mellinger U,
Palombo-Kinne E, Kuhl H.
Effect of extended-cycle regimen with an oral contraceptive containing 30 mcg
ethinylestradiol and 2 mg dienogest on bleeding patterns, safety, acceptance,
and contraceptive efficacy.
Contraception 2011;84:133-43